Regulatory News Service
28 July 2016 at 07:00
This announcement contains inside information
Thursday, 28 July 2016
Pascal Soriot, Chief Executive Officer, commenting on the results said:
“Our performance in the first half was in line with expectations, reflecting the anticipated near-term patent expiry challenges and the phasing of Externalisation Revenue in 2016. Our Growth Platforms continued to advance and made up over 60% of Total Revenue. Importantly, our transformed pipeline is advancing quickly and delivering a rich flow of differentiated medicines, boding well for our return to growth.
Alongside positive results for our first potential Respiratory biologic medicine, benralizumab, and for Tagrisso in second-line lung cancer, we are encouraged by the rapid patient recruitment in our Immuno-Oncology durva/treme combination programmes. This strong scientific momentum is set to continue, in particular where we anticipate key Immuno-Oncology data.”
Downloads
H1 2016 Results announcement (PDF 12mb)
H1 2016 Presentation (PDF 1.4mb)
H1 2016 Clinical trials appendix (PDF 2.2mb)
H1 2016 Results transcript (PDF 229)